Free Trial
LON:PYC

Physiomics Interim Earnings Results & Report

Physiomics logo
GBX 0.45 -0.02 (-4.63%)
As of 09:58 AM Eastern

Physiomics reported Interim earnings on February 16, 2026. The company reported EPS of -GBX 0.10.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

Physiomics EPS Results

Actual EPS
-GBX 0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Physiomics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Physiomics Interim Earnings FAQ

Physiomics (LON:PYC) reported earnings of -GBX 0.10 per share for Interim. The report was announced on Monday, February 16, 2026.

Physiomics Earnings Headlines

Physiomics (LON:PYC) Posts Earnings Results
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.tc pixel
ISS weighs in on Physiomics ahead of general meeting
See More Physiomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Physiomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Physiomics and other key companies, straight to your email.

About Physiomics

Physiomics (LON:PYC) provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.

View Physiomics Profile